A Low-Carb Approach to Treat Type 2 Diabetes in Pediatric Patients
Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Mar 27, 2025
Trial Information
Current as of April 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
Background Type 2 diabetes (T2D) in teenagers is becoming a growing health concern. In the U.S., the number of children and teens diagnosed with T2D nearly doubled between 2002 and 2018. Experts predict that in the next 40 years, the number of young people with T2D could quadruple.
T2D in youth is different from T2D in adults. Teens with T2D have more insulin resistance and their bodies struggle to make enough insulin. Unfortunately, common diabetes medications do not stop the disease from getting worse. Better treatment options for young people with T2D are needed.
T2D happens when the b...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 12-18
- • Diabetes diagnosis \>3 months to ensure stable baseline glycemic control
- • HbA1C between 6.5- 8.5%
- • BMI \>85th percentile
- • Negative pancreatic autoantibodies
- • Stable dose of anti-diabetic drugs GLP-1, metformin, SGLT-2 inhibitors, for 3 months
- Exclusion Criteria:
- • Current insulin treatment
- • Renal impairment measured as creatinine \> 1 mg/dL
- • Hepatic dysfunction measured as AST and ALT \>100 IU/ml
Trial Officials
Ortal Resnick, MD
Principal Investigator
University of Alabama at Birmingham
About University Of Alabama At Birmingham
The University of Alabama at Birmingham (UAB) is a prominent academic institution and research hub dedicated to advancing healthcare through innovative clinical trials. Renowned for its commitment to medical discovery and education, UAB conducts cutting-edge research across a wide array of disciplines, including oncology, cardiology, neurology, and public health. With a robust infrastructure for clinical research, UAB fosters collaboration among interdisciplinary teams, leveraging state-of-the-art facilities and resources to enhance the translation of scientific findings into effective treatments and interventions. As a leader in clinical research, UAB aims to improve patient outcomes and contribute to the broader medical community through rigorous trial design and implementation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, Alabama, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Related Blog Entries
View all
